One factor that can contribute to resistance is the expression of PD-L1 on tumor cells or the tumor microenvironment, which can inhibit CAR-T cell activity as these cells express programmed cell death protein 1 (PD-1) [245]. Here, PDCD1 is linked to neoplasm.